丙肝已經治癒了,乙肝還會遠嗎?——看歌禮(01672.HK)如何在病毒性肝炎領域開疆拓土
北京時間10月5日17點30分,據諾貝爾獎官方網站公佈的消息,將2020年度諾貝爾生理學或醫學獎授予Harvey J. Alter博士、Michael Houghton博士和Charles M. Rice博士,以表彰他們對丙肝病毒的重要發現。據介紹,這三位科學家的發現使得診斷和開發新藥成為可能,拯救了數百萬人的生命。
在以上科學發現的基礎上,歌禮(01672.HK)的科學家們及時抓住機遇,將其快速轉化為治癒慢性丙肝患者的高質量產品——戈諾衞®和新力萊®。其中,戈諾衞®是由歌禮研發的中國首個本土原研抗丙肝1類創新藥,從臨牀試驗申請獲批到獲得新藥證書僅用時33個月,用藥12周,治癒率高達97%。歌禮用實際行動踐行 “因治癒而自由”的使命,為國家公共衞生重大傳染性疾病治療領域貢獻歌禮力量!基於歌禮具有國際競爭力的高效研發創新能力,國家衞計委遴選歌禮為十三五科技重大專項丙肝課題全國牽頭單位,戈諾衞®和新力萊®均獲十三五科技重大專項支持。
在成功攻克慢性丙肝之後,歌禮正在攀登攻克慢性乙肝的高峯。為了實現慢性乙肝的臨牀治癒,歌禮採用了別具一格的研發策略。一方面將其已上市的長效干擾素派羅欣®和目前已進入臨牀II期的皮下注射的PD-L1抗體ASC22作為基石藥物,將其與內部研發的針對新靶點的候選藥物相結合,以期有效提高臨牀治療效果;另一方面,將派羅欣®或PD-L1抗體ASC22與行業領軍企業的各類候選藥物合作,以形成包含多種機理的combo,從臨牀研發和商業化角度提高乙肝管線競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.